Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Gervais R, Le Caer H, Monnet I, Falchero L, Baize N, Olivero G, Thomas P, Berard H, Auliac JB, Chouaid C; Groupe Français de Pneumo-Cancérologie 0501 Team. Gervais R, et al. Among authors: falchero l. Clin Lung Cancer. 2015 Mar;16(2):100-5. doi: 10.1016/j.cllc.2014.10.002. Epub 2014 Oct 29. Clin Lung Cancer. 2015. PMID: 25467927 Clinical Trial.
An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.
LeCaer H, Barlesi F, Robinet G, Fournel P, Geriniere L, Bombaron P, Falchero L, Auliac JB, Crequit J, Chouaid C. LeCaer H, et al. Among authors: falchero l. Lung Cancer. 2007 Jul;57(1):72-8. doi: 10.1016/j.lungcan.2007.02.012. Epub 2007 Mar 27. Lung Cancer. 2007. PMID: 17391803 Clinical Trial.
Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R, Vergnenegre A, Barlesi F, Lena H, Fournel P, Falchero L, Berard H, Hureaux J, Le Caer H, Chavaillon JM, Geriniere L, Monnet I, Chouabe S, Robinet G; GFPC VINCR Team. Descourt R, et al. Among authors: falchero l. J Thorac Oncol. 2011 Feb;6(2):351-7. doi: 10.1097/JTO.0b013e318200f47e. J Thorac Oncol. 2011. PMID: 21164367 Free article. Clinical Trial.
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C; GFPC 0504 Team. LeCaer H, et al. Among authors: falchero l. Br J Cancer. 2011 Oct 11;105(8):1123-30. doi: 10.1038/bjc.2011.331. Epub 2011 Sep 20. Br J Cancer. 2011. PMID: 21934690 Free PMC article. Clinical Trial.
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C, Le Caer H, Corre R, Crequit J, Locher C, Falchero L, Dujon C, Berard H, Monnet I, Vergnenegre A. Chouaid C, et al. Among authors: falchero l. Clin Lung Cancer. 2013 Mar;14(2):103-7. doi: 10.1016/j.cllc.2012.04.006. Epub 2012 Jun 7. Clin Lung Cancer. 2013. PMID: 22682669 Clinical Trial.
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Pérol M, et al. Among authors: falchero l. J Clin Oncol. 2012 Oct 1;30(28):3516-24. doi: 10.1200/JCO.2011.39.9782. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949150 Clinical Trial.
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M. Bylicki O, et al. Among authors: falchero l. J Thorac Oncol. 2013 Jul;8(7):906-14. doi: 10.1097/JTO.0b013e31828cb505. J Thorac Oncol. 2013. PMID: 23591160 Free article. Clinical Trial.
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators. Borget I, et al. Among authors: falchero l. BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953. BMC Cancer. 2014. PMID: 25511923 Free PMC article. Clinical Trial.
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC. Besse B, et al. Among authors: falchero l. Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22. Clin Cancer Res. 2015. PMID: 25614446 Clinical Trial.
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R. Sassier M, et al. Among authors: falchero l. Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/j.lungcan.2015.05.005. Epub 2015 May 15. Lung Cancer. 2015. PMID: 26037036
83 results